

**University Hospital Tübingen delivers 1,000<sup>th</sup> fraction with its Elekta Unity MR-Linac**  
*Demonstrates commitment to providing patients with personalized precision radiation medicine for multiple cancer indications*

TÜBINGEN, Germany – Less than one year after installing its Elekta Unity magnetic resonance radiation therapy (MR/RT) system, the team of clinicians at University Hospital Tübingen in Germany have delivered their 1,000<sup>th</sup> radiation therapy fraction to a patient receiving treatment for prostate cancer. Many radiation therapy regimens divide the total radiation dose into two or more smaller doses, known as fractions, which are delivered in separate treatment sessions. The 1,000<sup>th</sup> fraction represents the 1,000<sup>th</sup> treatment session delivered with Elekta Unity.

“Achievement of this milestone by University Hospital Tübingen in such a short time demonstrates that Unity can be efficiently used to personalize treatments for many patients,” said Richard Hausmann, CEO at Elekta. “Importantly, these fractions have been used to treat nine different cancer indications, demonstrating the broad therapeutic potential of the system. We are proud to continue collaborating with clinicians and researchers to further enable precision radiation medicine.”

Elekta Unity combines two technologies: a state-of-the-art 1.5T MRI scanner and a best-in-class 7 MV linear accelerator, driven by breakthrough real-time adaptive radiotherapy software. It provides the ability to reshape the dose based on daily changes in shape, size and position of the tumor and surrounding healthy anatomy, as visualized with MRI, and then enables accurate dose delivery with real-time visualization of the tumor.

“At University Hospital Tübingen, we recognized that integrating online, real-time diagnostic quality MR images with linac-based radiation delivery was essential to advancing radiotherapy,” said Professor Dr. Daniel Zips, Medical Director, of University Hospital Tübingen’s Comprehensive Cancer Clinic. “The excellent imaging quality of Elekta Unity has enabled us to adapt each patient’s treatment in real time, which allows already today optimal sparing of normal tissues and potentially in the future to individualize the dose to the tumor. The ability to visualize and adapt what we treat makes Elekta Unity an important new treatment option for a wide variety of cancer indications, including hard-to-treat cancers and complex anatomies previously considered not optimal for radiation therapy.”

In addition to University Hospital Tübingen, nine other leading cancer centers with Unity are treating patients with similar success. To learn more, visit [elekta.com/Unity](https://www.elekta.com/Unity).

*Elekta Unity has CE mark and 510(k) clearance but is not available in all markets.*

# # #

**For further information, please contact:**

Oskar Bosson, Global EVP Corporate Communications and Investor Relations  
Tel: +46 70 410 7180, e-mail: [Oskar.Bosson@elekta.com](mailto:Oskar.Bosson@elekta.com)  
Time zone: CET: Central European Time



---

Raven Canzeri, Global Public Relations Manager  
Tel: +1 770 670 2524, e-mail: [raven.canzeri@elekta.com](mailto:raven.canzeri@elekta.com)  
Time zone: ET: Eastern Time

**About Elekta**

For almost five decades, Elekta has been a leader in precision radiation medicine. Our nearly 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to – and benefits from – more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit [elekta.com](http://elekta.com) or follow [@Elekta](https://twitter.com/Elekta) on Twitter.